Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum 89Bio Inc ETNB

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction... see more

Bullboard (NDAQ:ETNB)

View:
User Avatar Image
(216)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Jan 27, 2025 7:41am

Using technical analysis for this stock.

It looks like it will be taking off this morning,so good luck to all of you shareholders out there with this one.
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 6:17am

89bio, Inc. (NASDAQ:ETNB): A Promising Biopharmaceutical Com

https://beyondspx.com/2024/08/01/89bio-inc-nasdaqetnb-a-promising-biopharmaceutical-company-advancing-innovative-therapies/
Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities